Cell line name |
HT1080/DR4 |
Accession |
CVCL_6C48 |
Resource Identification Initiative |
To cite this cell line use: HT1080/DR4 (RRID:CVCL_6C48) |
Comments |
Population: Caucasian. Selected for resistance to: ChEBI; CHEBI_28748; Doxorubicin (Adriablastin; Adriamycin). Derived from site: In situ; Bone, pelvis, acetabulum; UBERON=UBERON_0001269. |
Sequence variations |
- Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
|
Disease |
Fibrosarcoma (NCIt: C3043) Fibrosarcoma (ORDO: Orphanet_2030) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Hierarchy |
Parent: CVCL_0317 (HT-1080) |
Sex of cell |
Male |
Age at sampling |
35Y |
Category |
Cancer cell line |
Publications | PubMed=2896069 Slovak M.L., Hoeltge G.A., Dalton W.S., Trent J.M. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res. 48:2793-2797(1988) PubMed=1976136; DOI=10.1093/jnci/82.19.1553 Zwelling L.A., Slovak M.L., Doroshow J.H., Hinds M., Chan D., Parker E., Mayes J., Sie K.L., Meltzer P.S., Trent J.M. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II. J. Natl. Cancer Inst. 82:1553-1561(1990) PubMed=1673331 Slovak M.L., Coccia M., Meltzer P.S., Trent J.M. Molecular analysis of two human doxorubicin-resistant cell lines: evidence for differing multidrug resistance mechanisms. Anticancer Res. 11:423-428(1991) |
Cross-references |
Cell line databases/resources |
cancercelllines; CVCL_6C48
|
Encyclopedic resources |
Wikidata; Q54896569
|
Entry history |
Entry creation | 23-Feb-2016 |
Last entry update | 19-Dec-2024 |
Version number | 16 |
---|